MediPoint: Cardiac Rhythm Management - Global Analysis and Market Forecasts

News provided by

Dec 09, 2013, 07:44 ET

NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Cardiac Rhythm Management - Global Analysis and Market Forecasts

http://www.reportlinker.com/p01921069/MediPoint-Cardiac-Rhythm-Management---Global-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices

MediPoint: Cardiac Rhythm Management - Global Analysis and Market Forecasts

Summary

Scope

- Annualized Cardiac Rhythm Management (CRM) market revenue, annual cost of disease and adoption pattern data from 2010-2012 and forecast for eight years to 2020.

- Key topics covered include strategic competitor assessment, next-generation technologies, market characterization, identification of unmet needs, reimbursement considerations, and implications for CRM market growth globally.

- Pipeline analysis: comprehensive data split across different stages of development, emerging trends and mechanisms of support under development, including investigation of energy harvesting batteries, telemetry, and cardiac resynchronization therapy devices.

- Analysis of the current and future market competition in the global Pacemaker (PM), Implantable Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy Pacemaker (CRT-P) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) markets, as well as insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global Pacemaker and ICD market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRM market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track device sales in the global PM, ICD, CRT-P, and CRT-D markets from 2010-2020.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 71.1 List of Tables 141.2 List of Figures 222 Introduction 252.1 Catalyst 252.2 Related Reports 262.3 Upcoming Related Reports 263 Disease Overview 273.1 Anatomy and Physiology 273.1.1 Risk Factors 283.1.2 Etiology 303.2 Pathophysiology 313.2.1 Cardiac Arrhythmias 313.3 Clinical Presentation 373.3.1 Symptoms 373.4 Diagnosis 383.4.1 Blood and Urine Diagnostic Procedures 383.4.2 Electrocardiography-Based Diagnostic Procedures 393.4.3 Computerized Tomographic Angiography 403.4.4 Electrophysiological Testing 403.4.5 Electromechanical Wave Imaging 403.4.6 Echocardiography 413.4.7 Tilt-Table Testing 413.4.8 Diagnostic and Electrophysiological Studies 413.4.9 New York Heart Association Scale 413.4.10 American College of Cardiology Scale 423.4.11 Level of Evidence 423.5 Epidemiology 433.5.1 Prevalence 434 Industry Overview 474.1 Overview 474.2 Clinical Outcomes 474.2.1 Pacemakers 474.2.2 ICDs 554.2.3 CRT-Ps 624.2.4 CRT-Ds 634.3 Procedure Trends 644.3.1 Single-Chamber Devices More Popular than Dual-Chamber Devices in Developing Economies 644.3.2 Cardiac Resynchronization Therapy Increasingly Popular Around the World 684.3.3 Device Reuse Programs to Transform Currently Wasted Resource 714.3.4 Hospital Market Growth 724.4 Market Access 724.4.1 US 724.4.2 Europe 744.4.3 Asia-Pacific 754.4.4 South America 764.4.5 Reimbursement Trends 774.5 Regulatory Issues/Recalls 894.5.1 Medtronic Pacemakers Recalled over Failure Risk, 2009 894.5.2 St. Jude Riata ICD Leads Recalled, 2011 894.6 Mergers and Acquisitions 904.6.1 Boston Scientific Acquires C.R. Bard's Electrophysiology Business 904.6.2 Sorin Group Closes Further Investment and Option-to-Buy in Enopace Biomedical 904.7 Key Partnerships 914.7.1 Leti Forms Partnership with Sorin, TIMA, Cedrat Technologies, Tronics and EASII IC 914.7.2 St. Jude Medical to Invest in Nanostim 914.7.3 Sorin Group Signs Supply Agreement for Boston Scientific Corporation Lotus Valve System 934.8 Economic Impact 934.8.1 Cost-Effectiveness of Pacemakers 934.8.2 Cost-Effectiveness of ICDs 944.8.3 Cost-Effectiveness of Cardiac Resynchronization Therapy 944.9 Market Drivers 954.9.1 Rapidly Increasing Patient Populations Suitable for Device Implantation to Drive Sales 954.9.2 Technological Advances and New Products in Pipeline to Drive Sales 1014.9.3 Evolving Indications for Cardiac Rhythm Management Therapy 1054.9.4 Imaging Guided Placement of Leads 1084.9.5 Cost-Saving Benefits of Remote Home Monitoring 1094.9.6 Growing Adoption of Device Use in Emerging Markets 1114.9.7 Increased Primary Prevention Procedures 1134.9.8 Increases in Implantation from Positive Clinical Trials 1154.9.9 Antibacterial Envelopes to Reduce Rates of Complication and Increase Device Safety 1164.9.10 Strong Portfolio of Pipeline Products from Key Players to Drive Future Growth of the Market 1164.9.11 Leadless Technology Eliminates Lead-Related Complications 1174.9.12 Diagnostic Rate Improvements Expected to Drive CRM Device Sales 1184.9.13 Increased Device Implantation in Pediatrics 1204.10 Market Barriers 1214.10.1 US Healthcare Reform May Impact US CRM Market Growth Adversely 1224.10.2 Increased Emphasis on Value-Based Payment Programs through Medicare and Cost-Effectiveness Research to Cause Competitive Pricing Pressure 1224.10.3 Innovative and Next-Generation Drug Therapy May Pose a Challenge to CRM Devices in the Future 1234.10.4 Slow Adoption of Remote Patient Monitoring Could Restrain Market Growth 1234.10.5 Lacking Reimbursement for Costly Devices in Emerging Markets 1244.10.6 Inconsistencies between Various Guidelines Affects Treatment 1244.10.7 Inappropriate Shock Rates May Thwart Potential CRM Patients 1254.10.8 Patient Education to Increase Awareness and Device Adoption 1254.10.9 Declining Average Selling Prices to Adversely Affect CRM Product Revenues 1265 Competitive Assessment 1285.1 Overview 1285.2 Global Market Share 1285.2.1 Pacemaker and CRT-P Market Company Share Globally 1285.2.2 ICD and CRT-D Market Company Share Globally 1305.3 Regional Market Share 1315.3.1 Pacemaker and CRT-P Market Company Share in the US 1315.3.2 ICD and CRT-D Market Company Share in the US 1325.3.3 Pacemaker and CRT-P Company Share in Europe 1335.3.4 ICD and CRT-D Market Company Share in Europe 1345.3.5 Pacemaker and CRT-P Market Company Share in Emerging Markets 1355.3.6 ICD and CRT-D Market Company Share in Emerging Markets 1365.3.7 Pacemaker and CRT-P Market Company Share in Japan 1375.3.8 ICD and CRT-D Market Company Share in Japan 1386 Unmet Needs 1396.1 Overview 1396.2 Leads and Electrode Development 1396.2.1 MRI-Compatible Generators and Leads 1406.2.2 Single-Lead Systems with Atrial Diagnostics 1426.3 Power-Supplying Batteries 1426.4 Energy-Harvesting Batteries 1436.5 Rates of Infection 1447 Pipeline Products 1457.1 Overview 1457.2 Pipeline Products by Phase in Development 1457.3 Pacemaker and CRT-P Product Profiles 1467.3.1 Aortic Pacemaker (Hadasit Medical Research Services & Development Ltd.) 1467.3.2 Cardiac Energy Harvesting Pacemaker (University of Michigan) 1477.3.3 Endurance Microgenerator (Endurance Rhythm) 1477.3.4 Implantable Dual-Chamber Pacemaker (MicroPort Scientific) 1487.3.5 Unconditional MRI-Compatible Implantable Pacemaker (Kenergy, Inc.) 1487.3.6 Tissue-Engineered Autonomous Pacemaker (Duke University) 1497.3.7 Wireless Cardiac Stimulation Device (EBR Systems, Inc.) 1497.4 ICD and CRT-D Product Profiles 1507.4.1 Atrial Defibrillator (SmartWave Medical Ltd.) 1507.4.2 CardiaLen (CardiaLen, Inc.) 1507.4.3 Chronicle (Medtronic) 1517.5 Clinical Trials to Watch 1527.5.1 Overview 1527.5.2 SELECT-LV Trial of WiCS-LV System (EBR Systems, Inc.) 1527.5.3 MultiPoint Pacing Clinical Trial of Quadra Assura CRT-D (Medtronic) 1547.5.4 MADIT-ASIA Trial with Invive CRT-P (Boston Scientific) 1557.5.5 MultiPoint Pacing IDE Study of Promote Quadra (St. Jude Medical) 1577.5.6 Post Approval Study of S-ICD System (Boston Scientific) 1587.5.7 ProMRI Study of the Evia/Entovis Pacemaker System 1607.5.8 MIRACLE EF Clinical Study of Consulta CRT-P (Medtronic) 1628 Current and Future Players 1658.1 Overview 1658.2 Trends in Corporate Strategy 1658.3 Biotronik 1668.3.1 Overview 1668.3.2 Portfolio Evaluation 1688.3.3 Commercial Positioning 1788.3.4 Company SWOT Analysis 1798.4 Boston Scientific 1798.4.1 Overview 1798.4.2 Portfolio Evaluation 1818.4.3 Commercial Positioning 1908.4.4 Company SWOT Analysis 1918.5 Impulse Dynamics 1918.5.1 Overview 1918.5.2 Portfolio Evaluation 1918.5.3 Commercial Positioning 1928.5.4 Company SWOT Analysis 1928.6 Medtronic 1938.6.1 Overview 1938.6.2 Portfolio Evaluation 1958.6.3 Marketed Products 1978.6.4 Additional Products 2058.6.5 Commercial Positioning 2078.6.6 Company SWOT Analysis 2098.7 Sorin Group 2098.7.1 Overview 2098.7.2 Portfolio Evaluation 2118.7.3 Marketed Products 2128.7.4 Commercial Positioning 2138.7.5 Company SWOT Analysis 2148.8 St. Jude Medical 2148.8.1 Overview 2148.8.2 Portfolio Evaluation 2158.8.3 Marketed Products 2178.8.4 Commercial Positioning 2308.8.5 Company SWOT Analysis 2319 Market Outlooks and Forecasts 2329.1 Market Outlooks and Forecasts by Market Segment 2329.1.1 Pacemaker Market by Device Type 2329.1.2 ICD Market by Device Type 2339.1.3 CRT-P Market 2349.1.4 CRT-D Market 2359.2 Market Outlooks and Forecasts by Geography 2369.2.1 US 2369.2.2 France 2459.2.3 Germany 2509.2.4 Italy 2559.2.5 Spain 2609.2.6 UK 2649.2.7 Japan 2709.2.8 China 2749.2.9 India 2799.2.10 Brazil 28510 Appendix 29010.1 Bibliography 29010.2 Abbreviations 30310.3 Report Methodology 30810.3.1 Overview 30810.3.2 Coverage 30810.3.3 Secondary Research 30810.3.4 Forecasting Methodology 30910.3.5 Primary Research - Key Opinion Leader Interviews 31010.3.6 Expert Panel Validation 31110.4 Physicians and Specialists Included in this Study 31110.5 About the Authors 31310.5.1 Analysts 31310.5.2 Global Head of Healthcare 31410.6 About MediPoint 31510.7 About GlobalData 31510.8 Disclaimer 315

1.1 List of Tables

Table 1: New York Heart Association Scale 42

Table 2: American College of Cardiology Scale 42

Table 3: Level of Evidence 43

Table 4: Prevalent Cases of Congestive Heart Failure, All Markets, Ages ?45 Years, Men and Women (n), 2012-2019 46

Table 5: Pacemaker Implantation Classification Guideline 49

Table 6: Patient Post-Operative Condition with ICD Implantation, 2012 56

Table 7: Level of Evidence Guidelines 60

Table 8: Single-Chamber Pacemakers versus Dual-Chamber Pacemakers, Sales Volume Comparison, by Country, 2012 65

Table 9: Single-Chamber ICDs versus Dual-Chamber ICDs, Sales Volume Comparison, by Country, 2012 66

Table 10: CRT-P versus Conventional Pacemakers, Sales Volume Comparison, by Country, 2012 69

Table 11: CRT-D versus Conventional ICD Products, Sales Volume Comparison, by Country, 2012 70

Table 12: Healthcare Expenditure by Payer (%) and Healthcare Expenditure per Capita ($), Global, 2011 78

Table 13: Medicare Standardized Payment Rates for Hospitals for Pacemaker/CRT-P Implantation 79

Table 14: Medicare Standardized Payment Rates for Hospitals for Pacemaker/CRT-P Replacement 80

Table 15: Medicare Standardized Payment Rates for Hospitals for ICD/CRT-D Implantation 80

Table 16: Medicare Standardized Payment Rates for Hospitals for ICD/CRT-D Replacement 81

Table 17: Percentage of Population Aged 65 Years and Older, by Country, 2005-2015 96

Table 18: Percentage of Smoking Population by Country (%), Global, 2010 97

Table 19: Percentage of Overweight and Obese Population (Aged 15 Years and Above), by Country, 2012 98

Table 20: Diabetes Prevalence Rates by Region (%), 20-79 Years, Global, 2007 & 2010 99

Table 21: Percentage of Hypertensive Population Aged 25 Years and Above (%), Global, 2010 100

Table 22: Technological Innovations, Cardiac Rhythm Management Devices 101

Table 23: Benefits of Quadripolar Lead Technology 103

Table 24: Updated Cardiac Resynchronization Therapy Guidelines 104

Table 25: Emerging Market Contribution, Global, 2009-2012 113

Table 26: Percent Primary Prevention Implantation by Country (%), ICD/CRT-D, Global, 2012 114

Table 27: Primary Prevention Cases by Country (%), ICD, Global, 2012 119

Table 28: Barriers in Access to Quality Healthcare Leading to Disparities in CRM Treatment 121

Table 29: Average Selling Price ($) Comparison, by Country, 2012 127

Table 30: Pacemaker and CRT-P Market, Global, Company Share (%), 2012 129

Table 31: ICD and CRT-D Market, Global, Company Share (%), 2012 130

Table 32: Pacemaker and CRT-P Market, US, Revenue ($) and Company Share (%), 2012 131

Table 33: ICD and CRT-D Market, US, Revenue ($) and Company Share (%), 2012 132

Table 34: Pacemaker and CRT-P Market, Europe, Revenue ($) and Company Share (%), 2012 133

Table 35: ICD and CRT-D Market, Europe, Revenue ($) and Company Share (%), 2012 134

Table 36: Pacemaker and CRT-P Market, Emerging Markets, Revenue ($) and Company Share (%), 2012 135

Table 37: ICD and CRT-D Market, Emerging Markets, Revenue ($) and Company Share (%), 2012 136

Table 38: Pacemaker and CRT-P Market, Japan, Revenue ($) and Company Share (%), 2012 137

Table 39: ICD and CRT-D Market, Japan, Revenue ($) and Company Share (%), 2012 138

Table 40: Product Profile - Aortic Pacemaker 146

Table 41: Product Profile - Cardiac Energy Harvesting Pacemaker 147

Table 42: Product Profile - Endurance Microgenerator 147

Table 43: Product Profile - MicroPort Pacemaker 148

Table 44: Product Profile - Kenergy Pacemaker 148

Table 45: Product Profile - Tissue-Engineered Autonomous Pacemaker 149

Table 46: Product Profile - Wireless Cardiac Stimulation Device 149

Table 47: Product Profile - Atrial Defibrillator 150

Table 48: Product Profile - CardiaLen 150

Table 49: Product Profile - Chronicle 151

Table 50: Clinical Trial for WiCS-LV System 152

Table 51: Clinical Trial for Quadra Assura CRT-D 154

Table 52: Clinical Trial for Invive CRT-P 155

Table 53: MultiPoint Pacing IDE Study for Promote Quadra 157

Table 54: Post Approval Study of S-ICD System 158

Table 55: ProMRI Study of the Evia/Entovis Pacemaker System 160

Table 56: MIRACLE EF Clinical Study of Consulta CRT-P 162

Table 57: Company Profile - Biotronik 168

Table 58: Product Profile - Cylos 990 171

Table 59: Product Profile - Effecta 172

Table 60: Product Profile - Evia/Entovis 173

Table 61: Product Profile - Estella 174

Table 62: Product Profile - Stratos 175

Table 63: Product Profile - Ilesto 7 175

Table 64: Product Profile - Lumax 178

Table 65: Biotronik SWOT Analysis, 2012 179

Table 66: Company Profile - Boston Scientific 180

Table 67: Product Profile - Advantio 183

Table 68: Product Profile - Altrua 184

Table 69: Product Profile - Cognis 185

Table 70: Product Profile - Energen 186

Table 71: Product Profile - Incepta 186

Table 72: Product Profile - Ingenio 187

Table 73: Product Profile - Invive 188

Table 74: Product Profile - Punctua 189

Table 75: Product Profile - S-ICD System 2.0 189

Table 76: Product Profile - Teligen 190

Table 77: Boston Scientific SWOT Analysis, 2012 191

Table 78: Company Profile - Impulse Dynamics 191

Table 79: Product Profile - Optimizer IVs 192

Table 80: Impulse Dynamics SWOT Analysis, 2012 192

Table 81: Company Profile - Medtronic 194

Table 82: Product Profile - Advisa 197

Table 83: Product Profile - Adapta 198

Table 84: Product Profile - Brava/Viva 199

Table 85: Product Profile - Consulta 200

Table 86: Product Profile - EnPulse 200

Table 87: Product Profile - EnRhythm 201

Table 88: Product Profile - Ensura MRI 201

Table 89: Product Profile - Evera 202

Table 90: Product Profile - Protecta 202

Table 91: Product Profile - Secura 203

Table 92: Product Profile - Syncra 204

Table 93: Product Profile - Revo 204

Table 94: Product Profile - Concerto 205

Table 95: Product Profile - EnTrust 206

Table 96: Product Profile - Maximo II 206

Table 97: Medtronic SWOT Analysis, 2012 209

Table 98: Company Profile - Sorin Group 211

Table 99: Product Profile - Esprit 212

Table 100: Product Profile - Paradym 212

Table 101: Product Profile - Reply 2000 213

Table 102: Sorin Group SWOT Analysis, 2012 214

Table 103: Company Profile - St. Jude Medical 215

Table 104: Product Profile - Accent 218

Table 105: Product Profile - Accent MRI 219

Table 106: Product Profile - Anthem 220

Table 107: Product Profile - Allure Quadra 221

Table 108: Product Profile - AnalyST Accel 221

Table 109: Product Profile - Assurity 222

Table 110: Product Profile - Current Accel 222

Table 111: Product Profile - Current Plus 223

Table 112: Product Profile - Ellipse 223

Table 113: Product Profile - Endurity 224

Table 114: Product Profile - Fortify Assura 224

Table 115: Product Profile - Fortify 225

Table 116: Product Profile - Microny 225

Table 117: Product Profile - Leadless Pacemaker 226

Table 118: Product Profile - Promote Plus 227

Table 119: Product Profile - Quadra Assura 228

Table 120: Product Profile - Unify Assura 228

Table 121: Product Profile - Unify Quadra 229

Table 122: Product Profile - Unify 229

Table 123: Product Profile - Zephyr 230

Table 124: St. Jude Medical SWOT Analysis, 2012 231

Table 125: Pacemaker Market, Global, Revenue ($m), 2010-2020 233

Table 126: ICD Market, Global, Revenue ($m), 2010-2020 234

Table 127: CRT-P Market, Global, Revenue ($m), 2010-2020 235

Table 128: CRT-D Market, Global, Revenue ($m), 2010-2020 236

Table 129: US Cardiac Rhythm Management Device Implantation 237

Table 130: Implantable Cardioverter-Defibrillators Patient Clinical History Breakdown (%), US, 2012 240

Table 131: Implanting Physician Training Status (%), US, 2012 241

Table 132: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, US, Revenue ($m), 2010-2020 243

Table 133: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, US, Revenue ($m), 2010-2020 244

Table 134: France Cardiac Rhythm Management Device Implantation 247

Table 135: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, France, Revenue ($m), 2010-2020 248

Table 136: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, France, Revenue ($m), 2010-2020 249

Table 137: Germany Cardiac Rhythm Management Device Implantation 252

Table 138: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Germany, Revenue ($m), 2010-2020 253

Table 139: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Germany, Revenue ($m), 2010-2020 254

Table 140: Italy Cardiac Rhythm Management Device Implantation 256

Table 141: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Italy, Revenue ($m), 2010-2020 258

Table 142: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Italy, Revenue ($m), 2010-2020 259

Table 143: Spain Cardiac Rhythm Management Device Implantation 261

Table 144: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Spain, Revenue ($m), 2010-2020 263

Table 145: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Spain, Revenue ($m), 2010-2020 264

Table 146: UK Cardiac Rhythm Management Device Implantation 266

Table 147: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, UK, Revenue ($m), 2010-2020 268

Table 148: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, UK, Revenue ($m), 2010-2020 269

Table 149: Japan Cardiac Rhythm Management Device Implantation 271

Table 150: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Japan, Revenue ($m), 2010-2020 272

Table 151: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Japan, Revenue ($m), 2010-2020 273

Table 152: China Cardiac Rhythm Management Device Implantation 276

Table 153: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, China, Revenue ($m), 2010-2020 277

Table 154: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, China, Revenue ($m), 2010-2020 278

Table 155: India Cardiac Rhythm Management Device Implantation 282

Table 156: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, India, Revenue ($m), 2010-2020 283

Table 157: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, India, Revenue ($m), 2010-2020 284

Table 158: Brazil Cardiac Rhythm Management Device Implantation 287

Table 159: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Brazil, Revenue ($m), 2010-2020 288

Table 160: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Brazil, Revenue ($m), 2010-2020 289

1.2 List of FiguresFigure 1: Types of Arrhythmia 31Figure 2: Generic Pacemaker Code 49Figure 3: Guide for Pacemaker Implantation 50Figure 4: Percent Dual-Chamber Pacemakers, by Country, 2010, 2013, 2020 65Figure 5: Dual-Chamber ICDs (%), by Country, 2009, 2013, 2020 66Figure 6: CRT-P versus Conventional Pacemakers, Sales Volume Comparison, by Country, 2012 69Figure 7: CRT-D versus Conventional ICD Products, Sales Volume Comparison, by Country, 2012 70Figure 8: Patient and General Population Preferences for CRM Device Reuse, US 71Figure 9: Healthcare Expenditure by Payer, Global, 2011 78Figure 10: Percentage of Population Aged 65 Years and Above, by Country, 2005-2015 96Figure 11: Diabetes Prevalence Rates, 20-79 Years, by Region, 2007-2010 99Figure 12: Percentage of Hypertensive Population Aged 25 Years and Above (%), Global, 2010 100Figure 13: Evaluating Effectiveness of Remote Home Monitoring 110Figure 14: Emerging Market Contribution, Global, 2009-2012 112Figure 15: Percent Primary Prevention Implantation by Country (%), ICD/CRT-D, Global, 2012 114Figure 16: Primary Prevention Cases by Country (%), ICD, Global, 2012 118Figure 17: Secondary Prevention Diagnosed Cases by Country (%), ICD, Global, 2012 119Figure 18: Diagnosed VT & VF Cases Receiving ICD by Country (%), ICD, Global, 2012 120Figure 19: Average Selling Price ($) Comparison, by Country, 2012 126Figure 20: Pacemaker and CRT-P Market, Global, Company Share (%), 2012 128Figure 21: ICD and CRT-D Market, Global, Company Share (%), 2012 130Figure 22: Pacemaker and CRT-P Market, US, Company Share (%), 2012 131Figure 23: ICD and CRT-D Market, US, Company Share (%), 2012 132Figure 24: Pacemaker and CRT-P Market, Europe, Company Share (%), 2012 133Figure 25: ICD and CRT-D Market, Europe, Company Share (%), 2012 134Figure 26: Pacemaker and CRT-P Market, Emerging Markets, Company Share (%), 2012 135Figure 27: ICD and CRT-D Market, Emerging Markets, Company Share (%), 2012 136Figure 28: Pacemaker and CRT-P Market, Japan, Company Share (%), 2012 137Figure 29: ICD and CRT-D Market, Japan, Company Share (%), 2012 138Figure 30: CRM Pipeline Products by Phase in Development 145Figure 31: Pacemaker Market by Device Type, Global, Revenue ($m), 2010-2020 232Figure 32: Pacemaker Market, Global, Revenue ($m), 2010-2020 233Figure 33: CRT-P Market, Global, Revenue ($m), 2010-2020 234Figure 34: CRT-D Market, Global, Revenue ($m), 2010-2020 235Figure 35: Cardiac Resynchronization Therapy Implantation, US, by Age (%), 2011 239Figure 36: Cardiac Rhythm Management Implantation by Sex (%), US, 2012 240Figure 37: Pacemaker Implantation by Payer, US, 2012 241Figure 38: Pacemaker Implantation by Hospital Size, US, 2012 242Figure 39: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, US, Revenue ($m), 2010-2020 243Figure 40: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, US, Revenue ($m), 2010-2020 244Figure 41: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, France, Revenue ($m), 2010-2020 248Figure 42: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, France, Revenue ($m), 2010-2020 249Figure 43: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Germany, Revenue ($m), 2010-2020 253Figure 44: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Germany, Revenue ($m), 2010-2020 254Figure 45: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Italy, Revenue ($m), 2010-2020 258Figure 46: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Italy, Revenue ($m), 2010-2020 259Figure 47: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Spain, Revenue ($m), 2010-2020 262Figure 48: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Spain, Revenue ($m), 2010-2020 263Figure 49: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, UK, Revenue ($m), 2010-2020 268Figure 50: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, UK, Revenue ($m), 2010-2020 269Figure 51: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Japan, Revenue ($m), 2010-2020 272Figure 52: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Japan, Revenue ($m), 2010-2020 273Figure 53: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, China, Revenue ($m), 2010-2020 277Figure 54: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, China, Revenue ($m), 2010-2020 278Figure 55: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, India, Revenue ($m), 2010-2020 283Figure 56: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, India, Revenue ($m), 2010-2020 284Figure 57: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Brazil, Revenue ($m), 2010-2020 288Figure 58: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Market, Brazil, Revenue ($m), 2010-2020 289